Aradigm to Present at the 8th Annual BIO Investor Forum on October 28
More News related to ARDM
- Aradigm Doses First Patient in Long-Term Phase 2 Study of a Novel Inhaled Ciprofloxacin Formulation for the Management of Respiratory Infections in Bronchiectasis
- Aradigm Announces Third Quarter 2009 Financial Results
- Aradigm to Present at the 8th Annual BIO Investor Forum on October 28
- Piper Jaffray Initiates Aradigm Corporation (ARDM) with a Buy
- Pacific Growth Initiates Coverage on Aradigm (ARDM) with a Buy
More News related to Press Releases
- Citigroup Starts JDS Uniphase (JDSU) at Buy
- Wells Fargo Initiates Coverage on American Medical Systems Holdings (AMMD) with an Outperform
- Wells Fargo Initiates Coverage on Varian Medical Systems (VAR) with a Market Perform
- Wells Fargo Initiates Coverage on SAVVIS, Inc. (SVVS) with a Market Perform
- KeyBanc Initiates Coverage on BWAY Holding (BWY) with a Hold; Significant Opportunity, But Near-Term Concerns
HAYWARD, Calif.--(BUSINESS WIRE)-- Aradigm Corporation (OTCBB: ARDM) (the "Company") today announced that President and Chief Executive Officer Igor Gonda, Ph.D., will present at the 2009 Annual BIO Investor Forum on Wednesday, October 28, 2009, at 12:30 p.m. Pacific time (3:30 p.m. Eastern time).
The event will be held at the Palace Hotel in San Francisco, CA.
Interested parties can access a live audio webcast and slide presentation at www.aradigm.com. An archived presentation will be available on the Company's Web site for 14 days.
About the BIO Investor Forum
The 8th Annual BIO Investor Forum, hosted by the Biotechnology Industry Organization (BIO), is an international conference featuring late-stage private and emerging public companies. The BIO Investor Forum will include healthcare venture and private equity investors, buy-side investors, and research analysts as well as business development executives from leading global pharmaceutical and biotechnology companies.
About Aradigm
Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. Current activities include self-initiated development programs addressing the treatment of cystic fibrosis, bronchiectasis, inhalation anthrax infections and smoking cessation.
More information about Aradigm can be found at www.aradigm.com.
Aradigm and the Aradigm Logo are registered trademarks of Aradigm Corporation.
Source: Aradigm Corporation
Related Categories
Press ReleasesStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
